First, we examined the expression of NF-κB components, AICDA, Akt, JAK2/STAT3, and IL6 in PC9 (adenocarcinoma with the EGFR exon 19 deletion) and PC9/GR (adenocarcinoma with the EGFR-TKI-resistant with T790M mutation) cells, using Western blotting and RT-PCR (Figure 1A). This evidence concerns the gene EGFR and adenocarcinoma.